Organizational context and taxonomy of health care databases

Utility of automated data in identifying femoral shaft and subtrochanteric (diaphyseal) fractures

In women age 45 years and older, enrolled in an integrated group practice in 2007, use of ICD9 diagnostic codes, including the "not otherwise specified" code (821.00) resulted in a high false-positive rate for identifying femoral diaphyseal fractures. Restriction to more specific site-codes missed 36% of these rare fractures.

INTRODUCTION

The aim of this study was to assess the utility of automated data in identifying the occurrence of femoral diaphyseal fractures.

METHODS

We identified all women age 45 years and older enrolled in a Pacific Northwest integrated group practice during 2007. Using the computerized database we selected all ICD9 codes that could be related to a femur fracture occurring in the diaphyseal region. We then quantified the percent of codes confirmed by medical record review to have occurred in the correct anatomic location during the year of interest (positive predictive value).

RESULTS

Of the 95,765 eligible women, 161 (0.17%) had an ICD9 diagnostic code potentially related to a femoral diaphyseal fracture in 2007; of these 58 (36%) had a fracture of the femoral diaphysis, and 38 (24%) of the fractures occurred in 2007. The most frequent code was 821.00, described as "femur fracture not otherwise specified", applied to 107 women; 21 of the 58 diaphyseal fractures had this code.

CONCLUSION

In this study, use of ICD9 codes that included the "not otherwise specified" code (821.00) resulted in a high false-positive rate for identifying diaphyseal fractures. However, restriction to more specific site codes would have missed at least 36% of the diaphyseal fractures. Furthermore, the codes did not provide any information about the characteristics of the fracture. Our findings support validating cases selected using ICD codes before they are used as a surrogate for the occurrence of femoral diaphyseal fractures.

Impact of the 2002 American society for Colposcopy and Cervical Pathology guidelines on cervical cancer diagnosis in a geographically diverse population of commercially insured women, 1999-2004

OBJECTIVE

To report the impact of the release of the 2002 American Society for Colposcopy and Cervical Pathology guidelines on the management of abnormal cytological findings on time to diagnosis of cervical cancer in an insured population.

METHODS

This retrospective study identified women with cervical cancer (invasive and carcinoma in situ) through commercially insured administrative claims data. The cervical cancer case definition required a claim for cervical cancer and a claim with a diagnostic procedure (colposcopy, conization, biopsy, or hysterectomy). Time to diagnosis was defined as days between the initial Pap screening and the diagnostic procedure.

RESULTS

Between 1999 and 2004, there were 3,325 women aged 18 to 64 years who met the case definition for cervical cancer. Median time to diagnosis decreased from 42 days (interquartile range = 23-93 d) to 36.5 days (interquartile range = 20.5-80 d) for women with invasive cancer after the guideline change. The number of follow-up Pap screenings before biopsy also decreased (p = .0067). Among women with carcinoma in situ whose initial Pap screening was completed by a family practice clinician, time to diagnosis was projected to be more than 9 days longer compared with those whose screening was performed by a gynecologist.

CONCLUSIONS

The 2002 American Society for Colposcopy and Cervical Pathology guidelines for the management of abnormal cytological findings seem to have had a positive impact on the time to diagnosis and Pap screening use before biopsy for women diagnosed with cervical cancer.

Reliability of Group Health Cooperative automated pharmacy data by drug benefit status

PURPOSE

Evaluate the reliability of health plan pharmacy records in determining medication use among seniors with and without a drug benefit.

METHODS

Subjects included 3610 seniors, enrolled in Group Health Cooperative's Medicare (GHC) + Choice program during 1998-1999, receiving care in an integrated group practice (IGP), and diagnosed with one or more of four chronic conditions (hypertension, diabetes, congestive heart failure, and coronary artery disease). We compared pharmacy records to self-reported medication use for antidepressant, antihypertensive, acid suppressant, cardiac, diabetic, hormone, and lipid lowering drugs.

RESULTS

Agreement between pharmacy records and self-report was substantial to almost perfect (prevalence-adjusted and bias-adjusted kappa (PABAK) range: 0.69 for antihypertensives to 0.95 for cardiac agents) among seniors with a drug benefit. Agreement was slightly less for seniors without a drug benefit (PABAK range: 0.51 for antihypertensives to 0.92 for cardiac agents) and differences varied by drug class. Among seniors without a benefit, the prevalence of medication use was lower when based on pharmacy records than when based on self-report for all medication classes of interest.

CONCLUSIONS

While GHC may not be representative of all health plans, our study indicates that health plan pharmacy records are a reliable source of data for seniors receiving care within an IGP. However, the reliability of pharmacy records appears better among seniors with a drug benefit. Researchers should consider factors such as drug benefit status when conducting studies using pharmacy data. More studies are needed in different populations and delivery systems, as well as over varied types of drug benefits.